News | January 20, 2022
Green chemistry approaches to synthesis could make a big difference to pharma product outputs
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
The company has 47 ANDA's pending approval with the U.S.FDA
Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
It is the first monoclonal antibody drug for use in any animal species
Subscribe To Our Newsletter & Stay Updated
